Dermatology Research

CADMUS Jr. Clinical Research Study

Does your child have moderate-to-severe plaque psoriasis?

Doctors at Saint Louis University at SSM Health Cardinal Glennon Children’s Hospital are conducting a clinical research study of children with moderate-to-severe plaque psoriasis. The CADMUS Jr. clinical research study will examine the safety and effectiveness of an investigational medication in children with this skin condition.

The study will enroll patients who are six to 11 years of age who have had a diagnosis of plaque psoriasis for at least six months.

Additional criteria apply and will be assessed at the screening visit. To learn more about the CADMUS Jr. clinical research study, please contact: SLU Dermatology Research (Ashley McWilliams, M.D.) at 314-256-3454 or dermresearch@slu.edu.

Chin Filler Study

Participants needed.

Study of an investigational filler to correct volume deficit in the chin (SLU IRB  No. 26908).

Dee Anna Glaser, M.D., at Saint Louis University Dermatology is recruiting persons who desire improvement of the appearance of the chin by adding chin volume. The purpose of this research study is to evaluate the safety and effectiveness of an investigational injectable gel for adding volume to the chin.

You may be eligible if you:

  • Are 22 years of age or older in good general health
  • Desire added chin volume to correct chin appearance
  • Meet the physician evaluated criteria for treatment
  • Agree to complete all study required visits and to prevent pregnancy for the length of the study
  • The study will last up to 14 months and will include multiple visits to the study site.

Eligible participants if chosen may receive the following:

  • Study treatment
  • Facial photos and evaluations
  • Research-related exams
  • Compensation for time and travel

To learn more about this study contact:

Anastasia Kurta, D.O.
Dermatology Research Fellow
314-256-3439
kurtaao@slu.edu

Adults With Pemphigus Vulgaris (PV)

Participants needed.

A randomized, double-blind, double-dummy, active-comparator, multicenter study that evaluates the efficacy and safety of Rituximab versus MMF in patients with Pemphigus Vulgaris. (SLU IRB No. 25123)

Pemphigus Vulgaris (PV) is a rare, severe autoimmune disease that causes fragile blisters on the skin and in the mouth. The blisters may become painful or infected.  Standard treatment generally includes treatment with corticosteroid medications.

This research is evaluating two different investigational medications to see if they can help people who have Pemphigus Vulgaris (PV). The purpose of this study is to assess the safety, tolerability and effectiveness of the medications in people with PV.

Participants will receive one of the two investigational (active) medications and one placebo (non-active) medication. Your participation may last up to 52 weeks during treatment and another 48 weeks of follow up after the last treatment dose.

You must meet the following criteria to become a study participant:

  • Are 18-75 years of age
  • Have a confirmed diagnosis of PV within the previous 24 months
  • Are willing to follow a study treatment plan, routinely scheduled study visits and other study tests and procedures
  • Are in stable health
  • Meet other entry criteria based on screening examinations

You will receive the following:

  • One investigational medication and one placebo medication
  • Study required physical exams and laboratory tests
  • Compensation for time and travel 

For more information contact:

Anastasia Kurta, D.O.
Dermatology Research Fellow
314-256-3439
kurtaao@slu.edu

Adults with Moderate to Severe Psoriasis

Participants needed.

Study comparing two injectable treatments for moderate to severe plaque psoriasis (SLU IRB No. 27193).

M. Yadira Hurley, M.D., is recruiting persons with moderate to severe plaque psoriasis. The purpose of this research study is to evaluate and compare the safety and effectiveness of two FDA approved injectable medications for treatment of psoriasis.

You may be eligible if you:

  • Are 18 years of age or older in good general health
  • Have moderate to severe plaque psoriasis
  • Meet the physician evaluated and laboratory criteria for treatment
  • Agree to complete all study required visits and to prevent pregnancy for the length of the study

The study will last up to 56 weeks and will include multiple visits to the study site.

Eligible participants if enrolled may receive the following:

  • Study treatment
  • Laboratory testing
  • Research-related exams
  • Compensation for time and travel

To learn more about this study contact:

Anastasia Kurta, D.O.
Dermatology Research Fellow
314-256-3439
kurtaao@slu.edu

Pediatric Psoriasis Topical Medication Study

Does your child have psoriasis?

We are looking for children who are at least 2 to 11 years of age with psoriasis to participate in an eight week research study of an investigational medication for psoriasis.

Qualified participants will receive:

  • Study-related medical evaluations by a dermatologist
  • Study-related medications
  • Compensation for time and travel

For more information, please call:

Anastasia Kurta, D.O.
314-256-3454
kurtaao@slu.edu

Closed Research Studies

Underarm Hyperhidrosis

A multicenter, randomized, double blind, vehicle-controlled study to evaluate the safety and the effect on sweat production of three concentrations of topically applied BBI-4000 gel in subjects with axillary hyperhidrosis.

PI: Dee Anna Glaser, M.D.

Open: 2015

Closed: 2016

Pediatric Atopic Dermatitis

A multicenter, randomized, double-blind, vehicle-controlled study of the safety and efficacy of AN2728 topical ointment, 2 percent in children, adolescents and adults (ages 2 years and older) with atopic dermatitis.

PI: Elaine Siegfried, M.D.

Open: 2014

Closed: 2015

Underarm Hyperhidrosis

A Phase 2, randomized, double-blind, vehicle controlled, comparator study of the effect of DRM04B and DRM04 in subjects with axillary hyperhidrosis.

PI: Dee Anna Glaser, M.D.

Open: 2014

Closed: 2015

Submental Fat

A multicenter, double-blind, placebo-controlled safety study of ATX-101 (deoxycholic acid injection) for the reduction of localized subcutaneous fat in the submental area in subjects with clinician-reported submental fat rating scale (CR-SMFRS) grade 1 or CR-SMFRS grade 4.

PI: Dee Anna Glaser, M.D.

Open: 2014

Closed: 2015

Acne

A safety and efficacy study to compare dapsone dermal gel with vehicle control in patients with Acne Vulgaris.

PI: Dee Anna Glaser, M.D.

Open: 2014

Closed: 2015